Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study
Among this cohort of US subspecialist-treated adults with severe asthma and clinically relevant allergy, biologics decreased the rates of exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations, regardless of biologic subgroup.
Authors
- Jennifer Trevor (ORCID: https://orcid.org/0000-0001-6072-6274)
- Andrew Lindsley (ORCID: https://orcid.org/0000-0003-2670-704X)
- Christopher S. Ambrose (ORCID: https://orcid.org/0000-0003-4175-7336)
- Weily Soong (ORCID: https://orcid.org/0000-0002-2701-7035)
- Reynold A. Panettieri (ORCID: https://orcid.org/0000-0003-0834-4636)
- Bradley E. Chipps
- Warner W. Carr
Institutions
- Rutgers, The State University of New Jersey (US)
- Amgen (United States) (US)
- University of Alabama at Birmingham (US)
- Capital Allergy and Respiratory Disease Center (US)
- AstraZeneca (Italy) (IT)
- Asthma Association (BG)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1016/j.jacig.2025.100590
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00